Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
LNA.PA
Strong BuyFull HouseAPPROVELNA Santé SA · Healthcare · France · $397M · Avg Vol: $133K/d
Quantitative scores are balanced, and the firm shows modest insider buying coupled with upward EPS revisions. It meets the requirements for a quality-focused portfolio.
COMPANY DESCRIPTION
LNA Santé SA operates healthcare facilities, post-acute care clinics, rehabilitation centers, and specialized nursing homes across France and Belgium. The company's moat is secured by stringent government healthcare licensing requirements and high capital barriers to entry for medicalized care beds. LNA Santé operates as a premium, highly specialized healthcare operator focusing on clinical-heavy, high-dependency care models.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 728.2M | 736.1M | 806.6M | 912.7M | 7.8% | 913.2M | 990.2M | 1.0B | 7.0% |
| EPS (EUR) | 2.49 | 2.29 | 2.13 | 2.35 | -1.9% | 2.35 | 2.88 | 3.29 | 18.3% |
| Shares | 10.4M | 10.2M | 10.2M | 10.3M | -1.7% | 10.3M | — | — | — |
| Debt | 911.5M | 886.7M | 875.2M | 906.4M | -0.2% | 907.8M | — | — | — |
| Equity | 289.3M | 299.2M | 313.8M | 330.3M | 4.5% | — | — | — | — |
| Op CF | 103.2M | 97.5M | 110.4M | 99.4M | -1.2% | 99.5M | — | — | — |
| Inv CF | -42.0M | -15.7M | -23.7M | -14.2M | — | — | — | — | — |
| Fin CF | -110.9M | -106.7M | -88.8M | -65.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LNA.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LNA.PA | LNA Santé SA(you) | $397M | 97 | Strong Buy |
| CLARI.PA | Clariane SE | $1.6B | 79 | Buy |
| EMEIS.PA | emeis Société anonyme | $2.4B | 59 | Hold |
| BOI.PA | Boiron SA | $509M | 99 | Strong Buy |
| BLC.PA | Bastide Le Confort Médical SA | $186M | 94 | Strong Buy |
| VETO.PA | Vetoquinol SA | $946M | 94 | Strong Buy |
| LBIRD.PA | Lumibird SA | $651M | 80 | Buy |
| ALERS.PA | Eurobio Scientific Société anonyme | $233M | 73 | Buy |
| VIRP.PA | Virbac SA | $3.1B | 87 | Strong Buy |
| GBT.PA | Guerbet SA | $112M | 53 | Hold |
Peer medians: ROE -42.5% · P/E 23.5x · Gross margin 73.0%